A groundbreaking interdisciplinary initiative, spearheaded by researchers at the Massachusetts Institute of Technology (MIT) and Stanford University, has unveiled an innovative therapeutic strategy designed to reawaken the body’s own defenses against malignant growths. This sophisticated approach aims to significantly broaden the patient population that can benefit from the transformative potential of cancer immunotherapy, a field dedicated to harnessing the immune system’s power to combat disease.
At the core of this pioneering research lies a novel mechanism engineered to dismantle a critical "off switch" that tumors cunningly employ to neutralize the cytotoxic activity of immune cells. This inherent protective shield, which cancer cells deploy to evade immune surveillance, is intrinsically linked to complex sugar molecules known as glycans, which adorn the external surfaces of these aberrant cells. The scientific team has demonstrated that by strategically impeding the function of these glycans, using specifically designed protein constructs, they can dramatically amplify the immune system’s capacity to recognize and eradicate cancer cells.
To achieve this precise and potent immune activation, the researchers have engineered sophisticated, multi-functional molecular entities. These novel agents, dubbed "AbLecs," ingeniously integrate two key components: a lectin, a type of protein known for its ability to bind to sugars, and an antibody, a Y-shaped protein designed to specifically target and attach to tumor cells. This dual-targeting design ensures that the immune-boosting lectin is delivered directly to the vicinity of the cancer, maximizing its impact while minimizing off-target effects.
Dr. Jessica Stark, a distinguished figure in the departments of Biological Engineering and Chemical Engineering at MIT and a recipient of the prestigious Underwood-Prescott Career Development Professorship, articulated the significance of their creation. "We have developed a new class of protein-based therapeutics capable of neutralizing glycan-mediated immune checkpoints and augmenting anti-cancer immune responses," she stated. "Given the well-established role of glycans in suppressing anti-tumor immunity across a spectrum of cancer types, we are optimistic that our molecular constructs could offer novel and potentially more efficacious treatment avenues for a considerable number of cancer patients."
Dr. Stark, who is also an integral member of MIT’s Koch Institute for Integrative Cancer Research, served as the lead author of the seminal study detailing these findings. The research was further strengthened by the senior authorship of Dr. Carolyn Bertozzi, a renowned Professor of Chemistry at Stanford University and Director of the Sarafan ChEM-H Institute. Their collaborative efforts culminated in the publication of their transformative discoveries in the esteemed scientific journal, Nature Biotechnology.
Understanding Cancer’s Sophisticated Immune Suppression Tactics
A paramount objective in contemporary cancer therapeutics is to cultivate an environment where the immune system can effectively identify and eliminate cancerous cells. Immunotherapy, particularly the class of drugs known as checkpoint inhibitors, represents a significant stride in this direction. These medications function by disrupting the aberrant communication pathways between specific proteins, notably PD-1 and PD-L1, which tumors exploit to disengage immune cells. By severing this inhibitory connection, these therapies effectively release a crucial brake that prevents immune cells, such as cytotoxic T lymphocytes, from launching their destructive assault on cancer.
The clinical landscape has already witnessed the approval of checkpoint inhibitors targeting the PD-1/PD-L1 axis for a variety of cancers. In a subset of patients, these treatments have been associated with the remarkable achievement of durable remission, offering profound hope. However, a substantial portion of individuals receiving these therapies experience limited or no discernible clinical benefit, underscoring the urgent need for alternative and supplementary treatment modalities.
This pronounced therapeutic gap has galvanized researchers to investigate other intricate mechanisms by which tumors subvert immune responses. One particularly promising avenue of inquiry involves the complex interplay between tumor-associated glycans and specific receptors present on immune cells.
The Sialic Acid-Siglec Axis: A Sugar-Based Immune Brake
Glycans, ubiquitous molecules found on the surfaces of virtually all living cells, play diverse biological roles. However, cancer cells frequently exhibit aberrant glycan structures that are either absent or significantly altered on healthy tissues. A prominent feature of many tumor-specific glycans is the presence of a particular sugar building block known as sialic acid. When these sialic acids engage with specialized lectin receptors on immune cells, they can trigger a potent immunosuppressive cascade, effectively dampening the immune response. The lectins that specifically recognize sialic acid are collectively termed Siglecs (sialic acid-binding immunoglobulin-type lectins).
"The binding of Siglecs, found on immune cells, to sialic acids on cancer cells effectively applies the brakes to the immune system’s response," explained Dr. Stark. "This interaction prevents the immune cell from becoming activated and initiating its attack to destroy the cancer cell, mirroring the inhibitory function observed in the PD-1/PD-L1 pathway."
Despite extensive exploration, no approved therapeutic agents currently directly target the Siglec-sialic acid interaction. Previous strategies have attempted to develop lectins that bind to sialic acids, thereby blocking their engagement with immune cell receptors. However, these efforts have encountered significant challenges, primarily due to the typically low binding affinity of isolated lectins, which prevents them from accumulating in sufficient quantities on the tumor cell surface to exert a meaningful therapeutic effect.
AbLecs: A Synergistic Combination of Antibody Delivery and Lectin Inhibition
To surmount the limitations of previous approaches, Dr. Stark and her team ingeniously devised a strategy that leverages antibodies as highly specific delivery vehicles for potent lectin-based inhibitors. The antibody component of the AbLec is engineered to recognize and bind to specific antigens overexpressed on cancer cells. Upon successful docking at the tumor site, the attached lectin moiety is positioned to bind to sialic acid residues on the cancer cell surface. This binding event effectively sequesters the sialic acid, preventing it from interacting with Siglec receptors on immune cells. The subsequent disruption of this immunosuppressive signaling pathway liberates the immune brake, permitting immune effector cells, including macrophages and natural killer (NK) cells, to mount a robust anti-tumor attack.
"Typically, the lectin-binding domain possesses a relatively low affinity, making it unsuitable for direct therapeutic use as a standalone agent," Dr. Stark elaborated. "However, by conjugating this lectin domain to a high-affinity antibody, we can ensure its precise localization to the cancer cell surface. Once there, it can effectively bind and block the immunosuppressive effects of sialic acids."
A Versatile and Modular Design Demonstrated in Preclinical Models
The research team initially constructed an AbLec prototype by employing trastuzumab, a well-established antibody that targets the HER2 receptor and is currently approved for the treatment of breast, gastric, and colorectal cancers. In this AbLec configuration, one arm of the trastuzumab antibody was surgically replaced with a carefully selected lectin, specifically either Siglec-7 or Siglec-9, chosen for their known interaction with sialic acid.
In rigorous in vitro experiments utilizing cultured cancer cells, this engineered AbLec demonstrably altered the behavior of immune cells, inducing them to engage in and successfully eliminate cancer cells.
Further validation of the AbLec’s therapeutic potential was conducted in immunocompromised mouse models engineered to express human Siglec receptors and antibody receptors. Following the intravenous administration of cancer cells that subsequently formed lung metastases, mice treated with the AbLec exhibited a significant reduction in the number of lung metastases compared to those treated with trastuzumab alone, highlighting the synergistic benefit of the combined approach.
Crucially, the researchers also showcased the inherent flexibility and modularity of the AbLec platform. They demonstrated the ability to readily substitute different tumor-targeting antibodies, such as rituximab (which targets CD20) or cetuximab (which targets EGFR), as well as to interchange the lectin component to inhibit other immunosuppressive glycan-receptor interactions. Furthermore, the platform is adaptable to target other known immune checkpoint proteins, including PD-1.
"The AbLec technology is fundamentally designed for plug-and-play modularity," Dr. Stark emphasized. "One can envision swapping out various decoy receptor domains to target different members of the Siglec receptor family, and similarly, the antibody component can be exchanged. This adaptability is paramount, as diverse cancer types express distinct antigens, allowing for tailored therapeutic interventions by modifying the antibody target."
Forward Trajectory and Funding Landscape
In anticipation of advancing this promising technology toward clinical application, Dr. Stark, Dr. Bertozzi, and their colleagues have established a new biotechnology company, Valora Therapeutics. This venture is dedicated to the development of lead AbLec candidates, with the ambitious goal of initiating human clinical trials within the next two to three years.
The groundbreaking research underpinning this therapeutic innovation was made possible through the generous support of various esteemed funding bodies. These include a Burroughs Wellcome Fund Career Award at the Scientific Interface, a Society for Immunotherapy of Cancer Steven A. Rosenberg Scholar Award, a V Foundation V Scholar Grant, the National Cancer Institute, the National Institute of General Medical Sciences, a Merck Discovery Biologics SEEDS grant, an American Cancer Society Postdoctoral Fellowship, and a Sarafan ChEM-H Postdocs at the Interface seed grant.
About the Author
